Citizens Reiterates Market Outperform on Allogene Therapeutics, Maintains $6 Price Target

Benzinga Newsdesk www.benzinga.com Negative 86.4%

Neg 86.4% Neu 0% Pos 0%

Citizens analyst Reni J. Benjamin reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Market Outperform and maintains $6 price target.